Ethinyl Estradiol And Norethindrone Acetate

Introduction Overview

Generic Name

ethinyl estradiol and norethindrone acetate

Brand Name

Lo Loestrin Fe

Dosage Form

oral tablet

Drug Class

Contraceptives

Pharmacokinetics

Absorption:
Lo Loestrin Fe contains ethinyl estradiol and norethindrone acetate which are well absorbed orally. Ethinyl estradiol exhibits high oral bioavailability due to its resistance to first-pass metabolism, allowing systemic exposure crucial for contraceptive efficacy. Norethindrone acetate is rapidly hydrolyzed to norethindrone, the active form, after oral administration, ensuring prompt onset of action. The absorption of both hormones is consistent, but gastrointestinal disturbances such as vomiting or diarrhea can impair absorption, thus potentially reducing contraceptive effectiveness. Clinical studies indicate steady plasma levels are achieved with daily dosing, supporting once-daily administration.

Distribution:
Ethinyl estradiol and norethindrone are lipophilic hormones that distribute widely in body tissues, with high affinity for sex hormone-binding globulin (SHBG) and albumin in plasma. Ethinyl estradiol exhibits moderate volume of distribution, facilitated by its ability to bind to estrogen receptors located throughout reproductive and non-reproductive tissues. Norethindrone also binds extensively to plasma proteins. Both hormones cross the placental barrier and are excreted in small amounts in breast milk. The distribution phase impacts tissue exposure, sustaining pharmacodynamic effects related to ovulation suppression.

Metabolism:
Both ethinyl estradiol and norethindrone acetate undergo extensive hepatic metabolism primarily via cytochrome P450 enzymes, especially CYP3A4. Ethinyl estradiol undergoes hydroxylation and conjugation (glucuronidation and sulfation), while norethindrone acetate is hydrolyzed to norethindrone and further metabolized by reduction and conjugation pathways. First-pass metabolism in the liver significantly influences plasma concentrations, and coadministration of enzyme-inducing drugs may alter exposure by accelerating metabolism, necessitating clinical vigilance. Metabolic profiles contribute to the hormonal balance crucial for contraceptive efficacy and side effect profiles.

Elimination:
Metabolites of ethinyl estradiol and norethindrone are eliminated primarily via renal and fecal routes after conjugation. The elimination half-life of ethinyl estradiol ranges from approximately 10 to 20 hours, while norethindrone exhibits a half-life of about 8 to 10 hours, allowing once-daily dosing with consistent plasma levels. The metabolites are excreted as glucuronide and sulfate conjugates in urine and bile. Impaired hepatic or renal function can alter elimination kinetics, potentially affecting hormone levels and risk of side effects. Steady-state concentrations are typically reached after multiple dosing within a few days.

Dosage Forms

Available Dosage Forms:
Lo Loestrin Fe is formulated as oral tablets designed as a 28-day pack including hormone-containing and non-hormone tablets. Specifically, the pack contains 24 blue tablets each with 1 mg norethindrone acetate and 10 mcg ethinyl estradiol, 2 white tablets each containing 10 mcg ethinyl estradiol, and 2 brown ferrous fumarate tablets which serve as reminder pills without hormonal activity.

Dosages for Adults and Adolescents:
The standard dosing regimen is one tablet daily taken orally at the same time each day for 28 consecutive days. The regimen consists of taking the 24 active blue tablets followed by 2 active white tablets and concluding with 2 non-hormonal brown tablets. This dosing is consistent for contraceptive use in adult women and adolescents who require effective prevention of pregnancy.

Specific Patient Populations:
Lo Loestrin Fe is not recommended for women who smoke and are over 35 years old due to increased cardiovascular risks. Use in women with BMI over 35 kg/m2 has not been sufficiently studied, and dosing decisions should be individualized. Patients with hepatic impairment or a history of thromboembolism should avoid using this medication. No dose adjustments are recommended solely based on age or renal impairment. For breastfeeding women, Lo Loestrin Fe is generally avoided due to reduction in milk supply caused by estrogen.

Clinical Guidelines:
It is crucial that the tablets are taken in the prescribed order following the directional arrows on the pack to maintain hormone levels and effectiveness. Missing one or more doses requires specific instructions to minimize pregnancy risk, including the use of backup contraception when needed. The 28-day cycle is designed to simulate a monthly period and promote compliance. Timing should be consistent each day for optimal efficacy.

Mechanism Of Action

Lo Loestrin Fe exerts its contraceptive effects primarily through the combined actions of ethinyl estradiol, an estrogen analog, and norethindrone acetate, a synthetic progestin. The primary mechanism involves the suppression of ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. By maintaining steady levels of estrogen and progestin, the secretion of gonadotropins—luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—is inhibited, preventing the mid-cycle LH surge necessary for follicular rupture and ovulation.

At the cellular level, ethinyl estradiol binds to estrogen receptors, modulating gene transcription to sustain a hormonal milieu that supports endometrial stability, which paradoxically leads to a thinner endometrial lining that discourages implantation. Concurrently, norethindrone acetate's progestogenic activity thickens cervical mucus by increasing mucopolysaccharide content, which physically impedes sperm penetration and migration through the cervical canal.

The biochemical interactions of these hormones induce alterations in the endometrium rendering it inhospitable to fertilized ovum implantation by promoting a secretory endometrium with decreased glandular development and stromal edema. This multifaceted action not only prevents fertilization but also reduces the probability of implantation in rare cases of fertilization.

In comparison to other combined oral contraceptives, Lo Loestrin Fe contains a notably low dose of ethinyl estradiol (10 mcg in most active pills) which is designed to maintain contraceptive efficacy while minimizing estrogen-related side effects such as thromboembolism and nausea. Clinical trials have demonstrated that despite the low dose, the combination achieves ovulation suppression across users effectively, balancing safety and tolerability. Ongoing research confirms that the pharmacodynamic profile supports efficient contraception with a favorable side effect profile.

Pharmacological Actions

Suppresses ovulation by inhibiting the hypothalamic-pituitary-ovarian axis
Thickens cervical mucus to impede sperm penetration and fertilization
Alters endometrial lining to reduce likelihood of implantation of fertilized egg
Provides hormonal contraception through combined estrogen and progestin activity
Regulates menstrual cycles resulting in more predictable bleeding patterns
Reduces menstrual blood loss and dysmenorrhea in some users
Modulates hormonal receptor activity affecting reproductive tissues
Exerts minimal androgenic activity owing to norethindrone acetate's profile
Has a lower estrogen dose to reduce risks of estrogen-related adverse effects
Offers non-contraceptive benefits such as cycle control and decreased ovarian cysts risk

Therapeutic Or Clinical Uses

Prevention of pregnancy in women seeking hormonal contraception
Management of menstrual cycle regularity and reduction of menstrual bleeding
Reduction of dysmenorrhea symptoms associated with menstrual cycles
Treatment to reduce the risk of ovarian cyst formation through ovulation suppression
Use in patients requiring low-dose estrogen contraceptives to minimize side effects
Alternative contraceptive option for women who tolerate combined oral contraceptives
Support in family planning by providing reversible pregnancy prevention
Potential off-label use in managing menstrual-related disorders such as acne

Side Or Adverse Effects

Increased risk of serious blood clots including deep vein thrombosis and pulmonary embolism
Elevated chance of stroke and myocardial infarction, particularly in smokers or women over 35
High blood pressure in some users during therapy
Gallbladder disease including cholelithiasis and biliary colic
Rare occurrence of benign and malignant liver tumors
Common side effects include spotting or breakthrough bleeding during initial months
Nausea and gastrointestinal upset especially when starting therapy
Breast tenderness and enlargement
Headache, including migraine exacerbation in susceptible patients
Acne flare or improvement depending on individual hormonal response
Reduced libido or sexual desire in some patients
Mood changes including depression or mood swings
Fluid retention causing bloating or weight fluctuation
Changes in skin pigmentation such as melasma
Visual disturbances or difficulty tolerating contact lenses

Precautions

Avoid use in women over 35 years old who smoke due to cardiovascular risks
Use cautiously in patients with a history of thromboembolic disorders or inherited clotting disorders
Monitor blood pressure periodically during treatment
Consider alternatives in women with uncontrolled hypertension or diabetes with end-organ damage
Discontinue prior to elective surgeries to reduce thrombosis risk
Advise patients about possible interactions with enzyme-inducing drugs that may reduce effectiveness
Assess history of migraines, particularly with aura, before prescribing
Inform patients about the potential for breakthrough bleeding especially in the first months
Screen for breast cancer as estrogens may promote hormone-sensitive tumors
Advise against use in patients with active liver disease or history of liver tumors
Caution should be exercised in women with gallbladder disease
Discuss potential mood changes and depression risk with patients
Emphasize adherence to daily dosing schedule to maintain contraceptive efficacy
Caution when co-administered with lamotrigine due to seizure risk alterations
Inform breastfeeding mothers about potential decrease in milk production

Warnings

Do not use if you are over 35 and smoke due to significantly increased risk of cardiovascular events
Increased risk of venous and arterial thromboembolism, which can be fatal
Risk of serious blood clots is elevated in the presence of obesity, immobilization, or surgery
Lo Loestrin Fe may increase blood pressure; monitor and discontinue if hypertension develops
Discontinue if symptoms of thrombotic events occur, such as leg pain, chest pain, or sudden vision loss
Use with caution in women with a history of severe migraines with neurological symptoms
Potential for liver tumors; discontinue if liver abnormality symptoms appear
Non-use or inconsistent use increases risk of unintended pregnancy
Birth control pills do not protect against HIV/AIDS or other sexually transmitted infections
Use backup contraception if vomiting or diarrhea occurs within 3-4 hours of pill ingestion
Missed pills increase risk of pregnancy; follow strict guidelines for missed doses and use backup
Should not be used in patients on certain Hepatitis C antiviral regimens due to increased liver enzyme levels
Potential signal for depression and mood disorders; psychiatric evaluation recommended if symptoms arise
Safety and efficacy in women with BMI greater than 35 kg/m2 have not been established
Excessive estrogen exposure may contribute to breast and cervical cancer risk with prolonged use

Contraindication

History of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, or retinal thrombosis
History of ischemic stroke or transient ischemic attack
History of myocardial infarction or coronary artery disease
Presence of certain heart valve or rhythm abnormalities that predispose to clot formation
Known inherited thrombophilias that increase clotting risk
Uncontrolled hypertension despite medical therapy
Diabetes mellitus with vascular complications (retinopathy, nephropathy, neuropathy)
History of severe migraine with aura
Current or past breast carcinoma or other estrogen-sensitive cancers
Active liver disease including hepatic tumors or impaired liver function
Concurrent use of hepatitis C protease inhibitors containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
Hypersensitivity to any component of the formulation
Smoking and age over 35 years old
Jaundice associated with previous hormonal contraceptive use or pregnancy (cholestasis)
Pregnancy or suspected pregnancy

Drug Interactions

Barbiturates (e.g., phenobarbital) may reduce the effectiveness by inducing hepatic enzymes
Bosentan, a pulmonary arterial hypertension drug, may decrease contraceptive hormone levels
Carbamazepine, an anticonvulsant, induces CYP3A4 metabolism, reducing efficacy
Felbamate may accelerate metabolism of contraceptive steroids
Griseofulvin, an antifungal, compromises hormonal levels via enzyme induction
Oxcarbazepine induces liver enzymes decreasing hormonal contraceptive levels
Phenytoin lowers plasma concentrations of combined oral contraceptives reducing efficacy
Rifampin and rifabutin are potent inducers of hepatic enzymes that reduce hormone levels
St. John’s wort, an herbal supplement, induces metabolism and decreases contraceptive effect
Topiramate, used for epilepsy, may reduce contraceptive effectiveness at higher doses
Lamotrigine levels can be decreased when combined with contraceptives; dose adjustment required
Certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors may alter hormone levels
Enzyme inhibitors like ketoconazole may increase estrogen or progestin concentrations
Smoking can potentiate adverse cardiovascular effects when combined with estrogens
Antibiotics outside of rifampin class generally do not affect contraceptive efficacy significantly but monitoring is recommended

Preparations Of The Drug

Blue tablets contain 1 mg norethindrone acetate and 10 mcg ethinyl estradiol
White tablets contain 10 mcg ethinyl estradiol alone
Brown tablets contain ferrous fumarate (iron supplement) without hormones, serving as reminder pills
Inactive ingredients in blue tablets include mannitol, microcrystalline cellulose, FD&C Blue No. 1 Aluminum Lake, sodium starch glycolate, magnesium stearate, povidone, vitamin E, and lactose monohydrate
Inactive ingredients in white tablets include mannitol, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, povidone, vitamin E, and lactose monohydrate
Inactive ingredients in brown tablets include ferrous fumarate, mannitol, povidone, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sucralose, and spearmint flavor
Formulated as a 28-day triphasic oral contraceptive pack containing a sequence of active and reminder tablets
Manufactured and distributed by Allergan USA, Inc., Madison, NJ
Packaging designed for ease of adherence including day labels and directional arrows
Sterile, non-pyrogenic oral tablets designed for once-daily administration
The ferrous fumarate in brown tablets is not sufficient for treatment of iron deficiency but serves as compliance reminder
No generic equivalents are currently approved for this specific formulation
Supplied in blister packs to maintain tablet stability and protect from moisture
Storage recommendations: store at controlled room temperature, 25º C (77º F)
Drug has been formulated to optimize bioavailability and maintain hormone stability through shelf life